FindTrial
Sign In

MT-2990

DRUG5 trials

Sponsors

Tanabe Pharma Corporation, Tanabe Pharma America, Inc., Mitsubishi Tanabe Pharma Corporation

Conditions

Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)Endometrial Related PainHealthySeasonal Allergic Rhinitisontstekingsziektes. inflammation

Phase 1

A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers
CompletedNCT03156738
Tanabe Pharma CorporationHealthy
Start: 2017-05-17End: 2017-12-29Updated: 2018-01-18
A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients
CompletedNCT03570957
Tanabe Pharma CorporationSeasonal Allergic Rhinitis
Start: 2018-07-17End: 2018-12-27Updated: 2025-12-11
An Exploratory Study of MT-2990 in Patients With AAV
CompletedNCT06196905
Tanabe Pharma CorporationAntineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)
Start: 2024-06-24End: 2026-01-14Updated: 2026-02-04

Phase 2

Safety and Efficacy Study of MT-2990 in Women With Endometriosis
CompletedNCT03840993
Tanabe Pharma America, Inc.Endometrial Related Pain
Start: 2019-01-15End: 2021-10-05Updated: 2025-12-31

Unknown Phase

A randomised, double-blind, placebo-controlled, study to investigate the safety, tolerability and pharmacokinetics of single ascending doses of MT-2990 in healthy male subjects.
Active, not recruitingNL-OMON45915
Mitsubishi Tanabe Pharma Corporationontstekingsziektes. inflammation
Start: 2017-05-08Target: 48Updated: 2024-02-28